StemGenex Biologic Laboratories

StemGenex Biologic Laboratories was a San Diego-based healthcare company that specialized in providing adipose-derived stem cell therapies for patients with degenerative and autoimmune diseases. The company operated as a direct-to-consumer clinic, offering treatments for conditions such as Parkinson's disease, multiple sclerosis, and rheumatoid arthritis using stromal vascular fraction (SVF) extracted from patients' own fat tissue. StemGenex faced significant regulatory and legal challenges, including a 2018 FDA warning letter for marketing unapproved stem cell products and failing to comply with current good manufacturing practices (cGMP). Following a high-profile class-action lawsuit regarding deceptive marketing practices, the company ceased its primary operations. It is currently considered inactive after undergoing legal and financial dissolution.